問卷

TPIDB > Search Result

Search Result

篩選

List

1450Cases

2023-05-01 - 2025-12-31

Phase I

Active
An Open Label, Phase 1, Treatment Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of IDE397 (MAT2A Inhibitor) In Adult Participants With Advanced Solid Tumors
  • Condition/Disease

    Solid Tumor

  • Test Drug

    錠劑 注射用凍晶粉末

Participate Sites
2Sites

Recruiting2Sites

2024-09-01 - 2028-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
14Sites

Recruiting14Sites

2025-06-01 - 2029-04-30

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2023-04-17 - 2026-12-31

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2019-05-01 - 2025-12-31

Phase I/II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2020-02-05 - 2026-12-31

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2025-09-01 - 2032-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2024-02-01 - 2026-04-30

Phase I

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2025-03-01 - 2029-03-01

Phase III

Active
A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 3 Clinical Study to Assess Efficacy and Safety of Ropeginterferon alfa-2b (P1101) in Adult Patients with Pre-fibrotic/Early Primary Myelofibrosis or Overt Primary Myelofibrosis at Low or Intermediate-1 Risk According to DIPSS Plus (HOPE-PMF): The Core Study and Its Extension Study
  • Condition/Disease

    Pre-fibrotic/Early Primary Myelofibrosis or Overt Primary Myelofibrosis at Low or Intermediate-1 Risk According to DIPSS Plus (HOPE-PMF): The Core Study and Its Extension Study

  • Test Drug

    injection

Participate Sites
14Sites

Recruiting14Sites

2025-03-01 - 2026-09-30

Phase I

Active
  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites